Part of the work needed to ensure the overall well-being of neuropathy patients is to help them manage their moods and let them know that…
Rumination and Response - a Column by Ezekiel Lim
May 2020 has arrived, introducing warmer temperatures and beautiful days — the spring season, a great time to be outside. When it’s not raining, warmer…
Staying positive and maintaining mental health may be challenging during self-quarantine. For neuropathy patients, whether they have diabetic neuropathy, familial amyloid polyneuropathy, or…
Patients with peripheral neuropathy symptoms must practice caution when managing underlying symptoms by conferring with their doctors. One nerve damage treatment strategy to…
The COVID-19 pandemic has surged to unprecedented levels. Since last week’s column, many schools, workplaces, and public gatherings have been placed on hold. For…
By now the virus that causes COVID-19 has expanded to numerous countries, causing a global crisis. Because older people and those with preexisting health conditions…
The presence of peripheral neuropathy symptoms such as numbness, tingling, and burning sensations in the hands and feet might lead to…
Daylight saving time marks the seasonal transition between the colder months and the warmer months. The “fall back” transition to colder temperatures gifts the population…
How to Prevent Caregiver Burnout
Burnout among caregivers of patients suffering from peripheral neuropathy symptoms can become problematic for patients, family members, and caregivers themselves. Familial…
The numbness and tingling sensations associated with peripheral neuropathy may significantly impact a patient’s everyday life. Tasks such as cooking, cleaning, grocery shopping, and…
Recent Posts
- Scientists ID blood markers that predict heart risk in ATTR-CM
- Navigating amyloidosis treatment can be challenging for older adults
- Tiny skin biopsies may help diagnose transthyretin amyloidosis: New study
- Early diagnosis, treatment improves survival in ATTR-CM: Study
- FDA lifts clinical hold on Phase 3 trial of nex-z for hATTR-PN